Guselkumab demonstrated efficacy for achieving multidomain LDA/remission among patients with PsA and a prior inadequate response to TNF inhibitors.

Disease severity and insurance type are the major factors influencing the use of advanced systemic therapeutics in patients with atopic dermatitis.

Increased rates of congenital syphilis in the United States and continuum may be due to systemic barriers to comprehensive care and treatment.

A total of 5 distinct atopic dermatitis phenotypes and associated characteristics were identified among children using multi-omics profiling.

In news that suggests the U.S. opioid epidemic may be easing, drug overdose deaths fell 17% between July 2023 and July 2024.